Bayer Bids To Become Cell Therapy Manufacturing Leader

10 Oct 2023

The German group has invested $250m into a facility at its campus in Berkeley, CA to produce cell therapies from its own portfolio and for other companies in the space who are looking to tackle the perennial issue of manufacturing.

Bayer cell facility — The German major's new cell therapy facility • Source: Bayer

Bayer AG has opened the doors at a new multi-million dollar cell therapy production plant in the US to help overcome the manufacturing challenges that companies in the space have struggled to surmount.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

02 May 2025

• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

Gilead Pipeline Progress Offsets Oncology Sales Slowdown

25 Apr 2025

• By Alaric DeArment

Sales of the company’s approved cancer therapies were weaker or down, but Trodelvy is likely to see a label expansion and cell therapies are making progress.

In Brief: BriaCell’s Breast Cancer Cell Therapy Boosts Survival In Phase II

17 Apr 2025

• By Sushmita Panda

BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.

Cartesian Maps Out CAR-T Strategy With Simpler Logistics In Mind

08 Apr 2025

• By Alaric DeArment

The company announced positive Phase IIb data for Descartes-08 in myasthenia gravis, with especially strong efficacy among patients without prior biologic treatment.